|
VA Center for
Medication Safety - A Patient Safety Center for Inquiry
Drug Safety Features
[BACK TO TOP]
A .
LOOK-ALIKE/SOUND-ALIKE EFFORTS
1.
Alerts
PBM WARNING LETTER: Sulfasalazine and Sulfadiazine LA/SA Errors
Warning Letter - Sulfasalazine-Sulfadiazine LA-SA Errors
Look-Alike Sound-Alike Confusion Potential
with Humapen Memoir® and Humira® Pen – January 2007
Two Pens Different Uses; PBM Ez-Minutes January – March 2007
HUMIRA Pen and HumaPen;
ISMP Newsletter April 2007
Look-Alike Sound-Alike
Vaccine Mix-ups: Adacel (Tdap)
and Daptacel (DTaP) – August
24, 2006
ISMP
Newsletter
Fluarix® and Twinrix® Look-Alike
Confusion Potential
National
PBM Bulletin - Look-Alike Safety Alert Regarding Fluarix®
and Twinrix®
LOOK-ALIKE SAFETY ALERT FOR HALOPERIDOL AND
CYANOCOBALAMIN 1ML VIALS
National
PBM Bulletin
2. Pilot Project for Determining Look-alike Sound-alike Drug
Names for New Molecular Entities (NMEs)
a.
LASA Draft Paper
b.
Appendix I
c.
Appendix 2
d.
Appendix 3
3. Database
Evaluations/Tool
a.
General Information and Evaluation s for NMEs
4. VA-Specific
LA/SA pairs
5. JCHAO Guidance on LA/SA Drug
Names
a. Sentinel alert - May 1,
2001, Issue 19 : Look alike, sound alike drug names
b. JCHAO LA/SA
list
6. USP LA/SA list – USP Quality Review, March 2001, No. 76: Use
Caution – Avoid Confusion
[BACK TO TOP]
B. PHARMACOVIGILANCE AND DRUG SAFETY PROJECTS
1.
GENERAL SAFETY PROJECTS/PILOT PROJECTS
a. ADE
Reporting Project x
b. Off-Label
Use ADE Pilot Project
c. Drug-Drug
Interaction Pilot Project
d. Tablet-Splitting
Evaluation-An NCPS Collaboration
2.
SITE-BASED MEDICATION SAFETY EVALUATIONS
a. Conversion from Pravastatin
to Fluvastatin
b. Conversion to and Initiation
with Travoprost in Glaucoma Management
c. Safe and Appropriate Use of
Drotrecogin Alfa (Activated)
d. Impact of National Criteria
on Appropriate use of Tamsulosin in the VA
3.
RISK REDUCTION PROJECTS
a. Safety Initiative To Reduce Use Of Short-Acting Nifedipine
For HTN
b.
Cilostazol Safety Evaluation
c. High Dose Vitamin E Safety
Evaluation
d. Prevalence of α-1-Blocker
Monotherapy in Veteran Hypertensive Patients
e. Long Acting Beta Agonist (Monotherapy)
in Asthmatics
4.
DRUG SURVEILLANCE/PHARMACOVIGILANCE PROJECTS (Ongoing)
a. High Dose Statin
b.
Rosuvastatin
c. COX II Inhibitors
d.
Accutane
e.
Galantamine
f. Bisphosphonates
g. Thioridazine
h. Tiagabine
i.
Fluoroquinolone
j. Statin-Fibrate
k. Ezetimibe
l.
Bevacizumab
m. Atypical Antipsychotics
n. Leflunomide
o. Thiazolidinediones
p. Sibutramine
[BACK TO TOP]
C. POLICIES
1. Pharmaceutical Use Outside of Approved Indications Guidance
on Off-Label Prescribing
[BACK TO TOP]
D.
DRUG MARKET WITHDRAWALS
1.
Rofecoxib (Vioxx®)
a.
PBM Bulletin/News Alert
b.
Physician Notification Letter
c.
Pharmacist Notification Letter
d.
Dear Healthcare Provider Letter
e.
FAQ’s
f.
Patient Letter
2. Valdecoxib (Bextra®)
a.
Guidance
b.
Patient Letter
3. Natalizumab (Tysabri®) –
a.
FDA Public Health Advisory
b.
FDA Alert – Information for Healthcare Professionals
c.
Dear Healthcare Professional Letter – March 2005
d.
Dear Healthcare Professional Letter – April 2005
e.
FAQ’s on the Clinical Hold
f.
FAQ’s on Natalizumab
g.
Prescribing Information
h.
PBM Removal Communication and Actions
i.
Important Drug Warning Letter from Biogen/Idec, Elan
j.
FDA Information on resumed
market
4. Gatifloxacin (Tequin®)
a.
Letter of Discontinuation from Bristol Myers Squibb – May 2006
b.
FDA Alert – Information for Healthcare Professionals – March
2006
c.
FDA Alert – Patient Information – March 2006
d.
Prescribing Information
5. Mivacurium (Mivacron®)
a.
FDA Drug Shortages
6. Tegaserod (Zelnorm®) and Discontinued Marketing – March 30, 2007
a. FDA News
b. Questions and Answers on Zelnorm
c. FDA Public Health Advisory
d. National PBM Bulletin
e. Tegaserod Provider Letter
f. Tegaserod Patient Letter
g. Restricted Use of Zelnorm – July 2007
7.
FDA Recalls,
Market Withdrawals, Safety Alerts
If you have a question pertaining to this website and only information contained in this website, please contact the PBM Webmaster. Please note: For questions pertaining to Health Care Benefits, please visit http://www.va.gov/Health_Benefits/. For questions pertaining to prescription renewal, please visit https://www.myhealth.va.gov/. Questions pertaining to your drug therapy or other medical questions should be referred directly to your Health Care Providers located at the VA facilities where you receive care.
|
